Sangamo Therapeutics (SGMO) Competitors $2.69 -0.13 (-4.61%) (As of 10:21 AM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends SGMO vs. MNKD, CLDX, DVAX, BCRX, NVAX, MYGN, INVA, OPK, IRWD, and EBSShould you be buying Sangamo Therapeutics stock or one of its competitors? The main competitors of Sangamo Therapeutics include MannKind (MNKD), Celldex Therapeutics (CLDX), Dynavax Technologies (DVAX), BioCryst Pharmaceuticals (BCRX), Novavax (NVAX), Myriad Genetics (MYGN), Innoviva (INVA), OPKO Health (OPK), Ironwood Pharmaceuticals (IRWD), and Emergent BioSolutions (EBS). These companies are all part of the "biotechnology" industry. Sangamo Therapeutics vs. MannKind Celldex Therapeutics Dynavax Technologies BioCryst Pharmaceuticals Novavax Myriad Genetics Innoviva OPKO Health Ironwood Pharmaceuticals Emergent BioSolutions Sangamo Therapeutics (NASDAQ:SGMO) and MannKind (NASDAQ:MNKD) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, valuation, institutional ownership, media sentiment, community ranking and earnings. Which has stronger earnings and valuation, SGMO or MNKD? MannKind has higher revenue and earnings than Sangamo Therapeutics. Sangamo Therapeutics is trading at a lower price-to-earnings ratio than MannKind, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSangamo Therapeutics$52.29M11.25-$257.83M-$0.75-3.76MannKind$267.20M6.12-$11.94M$0.0784.71 Does the MarketBeat Community prefer SGMO or MNKD? MannKind received 130 more outperform votes than Sangamo Therapeutics when rated by MarketBeat users. However, 62.67% of users gave Sangamo Therapeutics an outperform vote while only 60.04% of users gave MannKind an outperform vote. CompanyUnderperformOutperformSangamo TherapeuticsOutperform Votes45062.67% Underperform Votes26837.33% MannKindOutperform Votes58060.04% Underperform Votes38639.96% Which has more volatility and risk, SGMO or MNKD? Sangamo Therapeutics has a beta of 1.15, meaning that its stock price is 15% more volatile than the S&P 500. Comparatively, MannKind has a beta of 1.28, meaning that its stock price is 28% more volatile than the S&P 500. Do analysts rate SGMO or MNKD? Sangamo Therapeutics currently has a consensus target price of $7.00, indicating a potential upside of 148.23%. MannKind has a consensus target price of $8.67, indicating a potential upside of 46.15%. Given Sangamo Therapeutics' higher probable upside, equities analysts clearly believe Sangamo Therapeutics is more favorable than MannKind.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sangamo Therapeutics 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75MannKind 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14 Do institutionals and insiders hold more shares of SGMO or MNKD? 56.9% of Sangamo Therapeutics shares are held by institutional investors. Comparatively, 49.5% of MannKind shares are held by institutional investors. 2.8% of Sangamo Therapeutics shares are held by company insiders. Comparatively, 3.0% of MannKind shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Is SGMO or MNKD more profitable? MannKind has a net margin of 8.07% compared to Sangamo Therapeutics' net margin of -257.87%. MannKind's return on equity of -17.74% beat Sangamo Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Sangamo Therapeutics-257.87% -264.16% -107.24% MannKind 8.07%-17.74%8.68% Does the media favor SGMO or MNKD? In the previous week, MannKind had 1 more articles in the media than Sangamo Therapeutics. MarketBeat recorded 13 mentions for MannKind and 12 mentions for Sangamo Therapeutics. MannKind's average media sentiment score of 0.75 beat Sangamo Therapeutics' score of 0.36 indicating that MannKind is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sangamo Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral MannKind 5 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive SummaryMannKind beats Sangamo Therapeutics on 15 of the 19 factors compared between the two stocks. Ad Darwin2025 AI Stock Picks: 2 Hidden Gems Under $10/ShareThe AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months.👉[Click here to get your FREE report delivered instantly!] Get Sangamo Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SGMO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SGMO vs. The Competition Export to ExcelMetricSangamo TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$588.39M$2.98B$5.18B$9.31BDividend YieldN/A1.85%4.78%4.06%P/E Ratio-3.7645.47130.2217.53Price / Sales11.25420.221,246.14139.51Price / Cash55.68182.1341.2337.95Price / Book6.003.924.884.92Net Income-$257.83M-$42.03M$119.65M$225.78M7 Day Performance45.36%-3.37%16.62%-1.56%1 Month Performance48.42%7.95%16.34%6.68%1 Year Performance637.83%21.00%35.38%22.48% Sangamo Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SGMOSangamo Therapeutics1.8846 of 5 stars$2.69-4.6%$7.00+160.2%+579.4%$561.26M$52.29M-3.59480Analyst UpgradeGap DownMNKDMannKind3.5182 of 5 stars$6.46-1.2%$8.67+34.2%+50.5%$1.78B$198.96M93.43400News CoverageCLDXCelldex Therapeutics3.0716 of 5 stars$26.56+4.5%$62.25+134.4%-29.9%$1.76B$6.88M-9.89160DVAXDynavax Technologies4.8018 of 5 stars$12.97+0.1%$22.00+69.6%-5.6%$1.70B$260.81M100.00408News CoverageBCRXBioCryst Pharmaceuticals3.8591 of 5 stars$7.35-2.4%$15.60+112.2%+21.0%$1.52B$412.58M-12.34530Positive NewsNVAXNovavax3.8056 of 5 stars$9.16+0.5%$17.83+94.7%+66.7%$1.47B$847.25M-4.031,543MYGNMyriad Genetics4.5684 of 5 stars$14.41-0.1%$24.27+68.4%-33.4%$1.31B$823.60M-11.102,700INVAInnoviva1.9307 of 5 stars$18.67+0.5%N/A+18.6%$1.17B$310.46M26.93112Short Interest ↓Positive NewsOPKOPKO Health4.4495 of 5 stars$1.56-2.2%$2.75+76.8%+4.2%$1.06B$711.41M-8.343,930Positive NewsIRWDIronwood Pharmaceuticals4.1096 of 5 stars$3.55+0.6%$10.40+193.0%-68.3%$568.11M$442.73M-117.67220EBSEmergent BioSolutions4.1689 of 5 stars$8.98+5.9%$14.00+55.9%+268.9%$486.57M$1.09B-2.071,600Insider TradeNews Coverage Related Companies and Tools Related Companies MNKD Alternatives CLDX Alternatives DVAX Alternatives BCRX Alternatives NVAX Alternatives MYGN Alternatives INVA Alternatives OPK Alternatives IRWD Alternatives EBS Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SGMO) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredHealthcare Takes A Big Step Forward With The Help of A.I.To date, we've seen baseline AI models lay the groundwork. Tools like ChatGPT are useful, but they are still s...Wall Street Star | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored2025’s #1 Trump TradeAll the Energy You Need to Power Your Entire Life... Could Fit Inside This Single Soda Can. Three Companies...The Oxford Club | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredThis drone stock is setting up to transform medical supply deliveryDrone stocks are on a tear, with certain symbols seeing gains as high as 300% over just a matter of weeks.The Tomorrow Investor | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sangamo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sangamo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SGMO Stock Alerts